The FDA rolled out an expedited pilot program aimed at reducing bottlenecks in investigational new drug (IND) applications as part of the HHS initiative “Operation TrialBlazer.” The pilot is designed to apply more risk-proportionate judgments earlier and parallelize steps in submission preparation, while the agency said review standards and timelines remain unchanged.